AxoGen (AXGN) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
AxoGen, Inc. Reports 2018 Second Quarter Financial Results
August 1, 2018 4:17 PM EDTQ2 Revenue of $20.6 million, representing 36% growth over prior year; reiterates full year 2018 guidance
ALACHUA, Fla., Aug. 01, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today reported financial results and business highlights for the second quarter ended June 30, 2018.
Second Quarter 2018 Financial Results and Recent Business Highlights
Revenue of $20.6 million, up 36% compared to $15.2 million in the second quarter of 2017Revenue from direct sales channel continues to grow above 40% and now accounts for... More